We develop new
treatments for central
nervous system disorders.

We develop new
treatments for central
nervous system disorders.

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Latest News

  • Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

  • For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

  • At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

  • We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

Emalex Biosciences Named “Neuroscience Therapeutics Company Of The Year” by BioTech Breakthrough

November 27, 2024
Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industries CHICAGO, November 19, 2024 – Emalex Biosciences was named “Neuroscience Therapeutics Company of the Year” in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence ... Read more
Read More →

Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate

October 5, 2023
– Long-term safety data collected in pediatric patients treated with investigational drug ecopipam; durable treatment effect reported with no evidence of tachyphylaxis –  CHICAGO, October 5, 2023 – An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the ... Read more
Read More →

Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome

March 1, 2023
– Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe –  CHICAGO, March 1, 2023 – Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for the treatment of ... Read more
Read More →

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Latest News

  • Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

  • For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

  • At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

  • We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

JAMA Neurology Publishes Phase 3 Data on D1 Receptor Antagonist Ecopipam in Tourette Syndrome

By emalexadmin | May 26, 2026
Phase 3 data show delayed time to relapse and maintained tic improvement with investigational, first-in-class mechanism targeting dopamine pathway Phase 3 results published in JAMA Neurology showed that ecopipam, an investigational, first-in-class dopamine-1 (D1) receptor antagonist, delayed time to relapse compared to placebo and maintained ... Read more
Read More →

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

JAMA Neurology Publishes Phase 3 Data on D1 Receptor Antagonist Ecopipam in Tourette Syndrome

By emalexadmin | May 26, 2026
Phase 3 data show delayed time to relapse and maintained tic improvement with investigational, first-in-class mechanism targeting dopamine pathway Phase 3 results published in JAMA Neurology showed that ecopipam, an investigational, first-in-class dopamine-1 (D1) receptor antagonist, delayed time to relapse compared to placebo and maintained ... Read more
Read More →

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy 

By emalexadmin | April 29, 2026
— Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first‑in‑class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations.  — The late‑stage program in a high-need, specialized area of neuroscience expands Teva’s innovative medicines pipeline, aligns with commercial strengths and supports both near‑ and long‑term growth.  — Upon closing, Emalex shareholders to receive $700 million in cash with the possibility of up ... Read more
Read More →